Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
|Videos|November 4, 2021
Glucose-Lowering Agents Nothing Short of Beneficial for Advanced CKD Patients
Galindo explained how the use of glucose-lowering agents in patients with diabetes and low eGFR improved patient care.
Advertisement
Pharmacy Times spoke to Rodolfo Galindo, MD, associate professor at the Emory School of Medicine, about his session at the ASN 2021 conference titled "Use of Glucose-Lowering Agents and Glycemic Monitoring in Advanced CKD.”
Galindo explained how the use of glucose-lowering agents in patients with diabetes and low eGFR improved patient care.
Advertisement
Related to this article
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
5